Risk factors

The Trust holds ether with a $401 billion market cap, exposed to proof-of-stake migration risks and regulatory limitations on staking activities. Spot markets for ether remain largely unregulated and susceptible to security breaches, fraud, wash trading, and front-running. The Trust depends heavily on third-party custodians, prime brokers, and authorized participants with limited alternatives.

Customer concentration is exceptionally high, with the largest customer generating 48% and top five generating 74% of revenue in 2024.

Tenon Medical relies entirely on the commercial success of a single medical device, The Catamaran System.

Usio faces heavy cyber security, regulatory compliance, and fraud risks inherent in its payment processing and transaction services. The company carries a significant accumulated deficit of $68.0 million despite reporting 2024 net income of $3.3 million. Key personnel concentration around CEO Louis A. Hoch and concentrated reseller and bank relationships heavily influence operational continuity.

X4 Pharmaceuticals faces substantial operating losses and requires additional capital to fund its commercialization and development programs.

Zentalis is a clinical-stage biopharmaceutical company dependent on its sole product candidate, azenosertib, which has no approved products and generates no revenue.

Samsara’s risks center on scaling its IoT platform, devices, sales force, and international operations while remaining profitable.

AI demand is concentrated among a small number of large customers and cloud service providers, making expansion to broader buyers critical.

Communications revenue fell 7% in 2024 after growing 13%–55% annually from 2016–2023.

The company has no product sales and remains pre-revenue while developing and optimizing AirJoule units.

Aprea Therapeutics faces ongoing net losses with an accumulated deficit of $321.0 million and substantial doubt regarding its going concern status. The company relies heavily on a single contract manufacturer for active pharmaceutical ingredients without redundant supply arrangements. Patent protection depends largely on method-of-use and formulation claims rather than composition-of-matter patents for the API.

Heavy reliance on Amazon U.S. marketplace for product sales creates platform concentration risk.